<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-161699</identifier>
<setSpec>0210-4806</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Expression of proteins FGFR3, PI3K, AKT, p21Waf1/Cip1 and cyclins D1 and D3 in patients with T1 bladder tumours: clinical implications and prognostic significance</dc:title>
<dc:description xml:lang="en">Objective. To determine the differential protein expression of biomarkers FGFR3, PI3K (subunits PI3Kp110&amp;#945;, PI3KClassIII, PI3Kp85), AKT, p21Waf1/Cip1 and cyclins D1 and D3 in T1 bladder cancer versus healthy tissue and to study their potential role as early recurrence markers. Material and method. This is a prospective study that employed a total of 67 tissue samples (55 cases of T1 bladder tumours that underwent transurethral resection and 12 cases of adjacent healthy mucosa). The protein expression levels were assessed using Western blot, and the means and percentages were compared using Student's t-test and the chi-squared test. The survival analysis was conducted using the Kaplan-Meier method and the log-rank test. Results. Greater protein expression was detected for FGFR3, PI3Kp110&amp;#945;, PI3KClassIII, cyclins D1 and D3 and p21Waf1/Cip1 in the tumour tissue than in the healthy mucosa. However, these differences were not significant for PI3Kp85 and AKT. We observed statistically significant correlations between early recurrence and PI3Kp110&amp;#945;, PI3KClassIII, PI3Kp85 and AKT (P=.003, P=.045, P=.050 and P=.028, respectively), between the tumour type (primary vs. recurrence) and cyclin D3 (P=.001), between the tumour size and FGFR3 (P=.035) and between multifocality and cyclin D1 (P=.039). The survival analysis selected FGFR3 (P=.024), PI3Kp110&amp;#945; (P=.014), PI3KClassIII (P=.042) and AKT (P=.008) as markers of early-recurrence-free survival. Conclusions. There is an increase in protein expression levels in bladder tumour tissue. The overexpression of FGFR3, PI3Kp110&amp;#945;, PI3KClassIII and AKT is associated with increased early-recurrence-free survival for patients with T1 bladder tumours (AU)</dc:description>
<dc:creator>López Beltrán, A</dc:creator>
<dc:creator>Sánchez-González, A</dc:creator>
<dc:creator>Carrasco Valiente, J</dc:creator>
<dc:creator>Blanca Pedregosa, AM</dc:creator>
<dc:creator>Gómez Gómez, E</dc:creator>
<dc:creator>Ruiz García, JM</dc:creator>
<dc:creator>Requena Tapia, MJ</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Determinar la expresión proteica diferencial de los biomarcadores FGFR3, PI3K (subunidades PI3Kp110&amp;#945;, PI3KClassIII, PI3Kp85), AKT, p21Waf1/Cip1 y las ciclinas D1 y D3 en el cáncer de vejiga T1 versus tejido sano, así como estudiar su posible papel como marcadores de recidiva precoz. Material y método. Se trata de un estudio prospectivo en el que se utilizaron un total de 67 muestras de tejido (55 casos de tumores de vejiga T1 sometidos a resección transuretral y 12 casos de mucosa sana adyacente). Los niveles de expresión de las proteínas se evaluaron mediante Western blot, y las medias y los porcentajes fueron comparados utilizando el test «t» de Student y la prueba Chi cuadrado. El análisis de supervivencia se realizó mediante el método Kaplan-Meier y el test Log-rank. Resultados. Se detectó una mayor expresión proteica de FGFR3, PI3Kp110&amp;#945;, PI3KClassIII, ciclinas D1 y D3 y p21Waf1/Cip1 en tejido tumoral versus mucosa sana. Sin embargo, estas diferencias no fueron significativas para PI3Kp85 y AKT. Se observaron correlaciones estadísticamente significativas de PI3Kp110&amp;#945;, PI3KClassIII, PI3Kp85 y AKT con la recidiva temprana (p=0,003, p=0,045, p=0,050 y p=0,028 respectivamente), de ciclina D3 (p=0,001) con el tipo tumoral (primario versus recidivante), de FGFR3 (p=0,035) con el tamaño tumoral y de ciclina D1 (p=0,039) con la multifocalidad. El análisis de supervivencia seleccionó a FGFR3 (p=0,024), PI3Kp110&amp;#945; (p=0,014), PI3KClassIII (p=0,042) y AKT (p=0,008) como marcadores de supervivencia libre de recidiva precoz. Conclusiones. Existe un incremento de los niveles de expresión proteica en el tejido tumoral vesical, asimismo, la sobreexpresión de FGFR3, PI3Kp110&amp;#945;, PI3KClassIII y AKT se asocia con una mayor supervivencia libre de recidiva precoz en pacientes con tumores de vejiga T1 (AU)</dc:description>
<dc:source>Actas Urol Esp;41(3): 172-180, abr. 2017. tab, ilus, graf</dc:source>
<dc:identifier>ibc-161699</dc:identifier>
<dc:title xml:lang="es">Expresión de las proteínas FGFR3, PI3K, AKT, p21Waf1/Cip1 y ciclinas D1 y D3 en pacientes con tumores de vejiga T1: implicaciones clínicas y significado pronóstico</dc:title>
<dc:subject>^d11812</dc:subject>
<dc:subject>^d52438</dc:subject>
<dc:subject>^d23568^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d1774^s22016</dc:subject>
<dc:subject>^d1774^s22012</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d1774^s22053</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d9557^s22012</dc:subject>
<dc:subject>^d50719^s22002</dc:subject>
<dc:subject>^d30942^s22002</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d28224^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201704</dc:date>
</metadata>
</record>
</ibecs-document>
